1
|
Gouletsou PG, Zacharopoulou T, Skampardonis V, Georgiou SG, Doukas D, Galatos AD, Flouraki E, Dermisiadou E, Margeti C, Barbagianni M, Sideri A, Tsioli V. First-Intention Incisional Wound Healing in Dogs and Cats: A Controlled Trial of Dermapliq and Manuka Honey. Vet Sci 2024; 11:64. [PMID: 38393082 PMCID: PMC10892332 DOI: 10.3390/vetsci11020064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2023] [Revised: 01/14/2024] [Accepted: 01/25/2024] [Indexed: 02/25/2024] Open
Abstract
This study aimed to compare incisional wound healing in cats and dogs after the topical application of Μanuka honey and a new medical device, Dermapliq. Comparisons were made between each treatment and control, between the two treatments, and between dogs and cats. Twelve cats and twelve dogs were included in this study, and the impact of the two substances was examined through cosmetic, clinical, ultrasonographical, and histological evaluation. The use of Dermapliq in first-intention wound healing achieved a significantly better cosmetic evaluation score and better total clinical score at days 20-41, compared to the control, in both dogs and cats. The ultrasonographically estimated wound area was smaller with Dermapliq compared to the control. Wounds treated with Dermapliq showed histologically less inflammation compared to the control. The use of Manuka honey did not show a significantly better cosmetic score compared to the control. Skin thickening was significantly higher after using Manuka honey compared to the control and so was the total clinical score. However, the median wound area, as was evaluated ultrasonographically, was significantly smaller when wounds were treated with Manuka honey, the difference being more apparent in dogs. Dermapliq was proven to be a better choice in achieving favorable wound healing than Manuka honey in dogs and cats in first-intention healing. In our study, cats had a statistically better cosmetic score and less skin thickening and scar width compared to dogs. Histologically, cats showed significantly less edema, higher inflammation and angiogenesis scores, and lower fibroblast and epidermis thickening scores when compared to dogs.
Collapse
Affiliation(s)
- Pagona G. Gouletsou
- Clinic of Obstetrics and Reproduction, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece
| | - Theodora Zacharopoulou
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| | - Vassilis Skampardonis
- Laboratory of Epidemiology, Biostatistics and Animal Health Economics, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece;
| | - Stefanos G. Georgiou
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| | - Dimitrios Doukas
- Laboratory of Pathology, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece;
| | - Apostolos D. Galatos
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| | - Eugenia Flouraki
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| | - Eleftheria Dermisiadou
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| | - Chryssoula Margeti
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| | - Mariana Barbagianni
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| | - Aikaterini Sideri
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| | - Vassiliki Tsioli
- Clinic of Surgery, Faculty of Veterinary Science, School of Health Sciences, University of Thessaly, Trikalon 224, 43100 Karditsa, Greece; (T.Z.); (S.G.G.); (A.D.G.); (E.F.); (E.D.); (C.M.); (M.B.); (A.S.); (V.T.)
| |
Collapse
|
2
|
Roohi SA, Keuylian Z, Barritault D. ReGeneraTing Agents (rgta ®) technology combined with antibiotics improves outcomes for infections in the upper limb. Clin Case Rep 2021; 9:1083-1091. [PMID: 33768787 PMCID: PMC7981774 DOI: 10.1002/ccr3.3645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2020] [Revised: 11/05/2020] [Accepted: 11/08/2020] [Indexed: 11/23/2022] Open
Abstract
A matrix therapy agent marketed as CACIPLIQ20® showed marked improvement in the healing rate of hand infections, including functional recovery. It can be used at both earlier and later stages to promote faster healing and prevent an adverse outcome.
Collapse
Affiliation(s)
- Sharifah Ahmad Roohi
- Hand & Upper Limb CentrePantai Hospital Kuala LumpurKuala LumpurMalaysia
- Prince Court Medical CentreOrthopaedic ClinicKuala LumpurMalaysia
| | | | - Denis Barritault
- OTR3ParisFrance
- Laboratory Cell Growth and Tissue Repair (CRRET)UPEC 4397/ERLCNRS 9215Université‐Paris‐Est‐CréteilCréteilFrance
| |
Collapse
|
3
|
Desgranges P, Louissaint T, Godeau B, Barritault D. Matrix therapy is a cost-effective solution to reduce amputation risk and improve quality of life: pilot and case studies. Regen Med Res 2019; 7:2. [PMID: 31821145 PMCID: PMC6902838 DOI: 10.1051/rmr/190002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2019] [Accepted: 11/11/2019] [Indexed: 11/29/2022] Open
Abstract
Introduction: Chronic, non-healing ulcers remain one of the most challenging clinical situations for health care practitioners. Often, conventional treatments fail and lead to amputation, further decreasing the patient's quality of life and resulting in enormous medical expenditures for healthcare systems. Here we evaluated the use of and cost-effectiveness of the RGTA (ReGeneraTing Agents) medical device CACIPLIQ20 (OTR4120) for chronic lower-extremity ulcers in patients with Leriche and Fontaine Stage IV peripheral arterial disease who were not eligible for revascularization. Methods: This uncontrolled pilot study included 14 chronic lower extremity ulcers in 12 patients in one hospital. The pilot study included 12 patients with TcPO2 < 20 mm Hg and ABPI < 0.5 who had either a minimum of one chronic lower extremity ulcer or a chronic ulcer related to amputation. OTR4120 was applied twice a week or until complete healing, for up to 12 weeks. Ulcer surface area reduction (%)after 2, 4, 8 and 12 weeks, appearance after 4 weeks, and healing after 12 weeks were measured and recorded. Results: A 35% reduction in ulcer size was achieved after 4 weeks. 7 (50%) out of 14 ulcers completely healed within 1 to 3 months of treatment. Discussion: OTR4120 is an effective therapeutic option for patients with chronic lower extremity ulcers, can provide major improvement of quality of life and has the added benefit of being a significant cost-effective solution for healthcare systems.
Collapse
Affiliation(s)
- Pascal Desgranges
- Department of Vascular Surgery, Hospital Henri Mondor, Université Paris-Est, Créteil 94010, France
| | - Taina Louissaint
- Department of Endocrinology, Hospital Henri Mondor, Université Paris-Est, Créteil 94010, France
| | - Bertrand Godeau
- Department of Endocrinology, Hospital Henri Mondor, Université Paris-Est, Créteil 94010, France
| | - Denis Barritault
- OTR3, SAS, 4 rue Française, 75001 Paris, France - CRRET (EA 4397/ERL CNRS 9215), Université Paris-Est, Créteil 94010, France
| |
Collapse
|
4
|
Irving S. Managing chronic, nonhealing wounds stalled in the inflammatory phase: a case series using a novel matrix therapy, CACIPLIQ20. Br J Community Nurs 2019; 24:S33-S37. [PMID: 31479338 DOI: 10.12968/bjcn.2019.24.sup9.s33] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
One of the biggest challenges faced by healthcare providers is the treatment of chronic, non-healing wounds. This paper reports for the first time in the UK the results of five case studies in which a novel regenerating matrix-based therapy, CACIPLIQ20, was used. CACIPLIQ20 is a heparan sulphate mimetic designed to replace the destroyed heparan sulphate in the extracellular matrix of wound cells. All five patients in this case series had chronic, non-healing ulcers that had not improved with conventional care. Treatment included two applications of CACIPLIQ20 per week, for a maximum of 12 weeks. Three of the five wounds healed completely, and the remaining two showed significant improvements in size and quality. The treatment was well tolerated by the patients and also led to a significant reduction in pain. Moreover, CACIPLIQ20 treatment was found to be highly cost-effective when compared to conventional care, with the potential to save healthcare systems significant resources. Further studies are needed to build a strong evidence base on the use of this product, but these preliminary findings are certainly promising.
Collapse
Affiliation(s)
- Sally Irving
- Tissue Viability Service Manager at Somerset Partnership NHS Trust, at the time of the study now, Independent Tissue Viability Nurse Consultant at Specialist Wound Care (Boocare Ltd)
| |
Collapse
|
5
|
Roohi SA, Barritault D. ReGeneraTing Agents (RGTA ®): A new option for healing and improving treatment outcomes for traumatic and burn injuries of the hand. Clin Case Rep 2019; 7:619-625. [PMID: 30997049 PMCID: PMC6452499 DOI: 10.1002/ccr3.2054] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2018] [Revised: 01/19/2019] [Accepted: 01/24/2019] [Indexed: 11/16/2022] Open
Abstract
CACIPLIQ20® significantly improved the outcomes of severe burn injuries of the hand. Healing was accelerated, with little or no scarring, allowing for greater mobility over the joints and maintained suppleness. Functional recovery was achieved in all cases.
Collapse
Affiliation(s)
- Sharifah Ahmad Roohi
- Department of Orthopaedics, Faculty of Medicine and Health SciencesUniversiti Putra MalaysiaSerdangSelangor Darul EhsanMalaysia
- Hand & Upper Limb CentrePantai Hospital Kuala LumpurKuala LumpurMalaysia
| | - Denis Barritault
- OTR3 (Organe, Tissue, Régénération, Réparation, Remplacement)ParisFrance
- Laboratory Cell Growth and Tissue Repair (CRRET), UPEC 4397/ERL, CNRS 9215Université‐Paris‐Est‐CréteilCréteilFrance
| |
Collapse
|